硫酸奈替米星与阿米卡星治疗重症监护病房中肺部感染的疗效比较  

Netilmicin versus amikacin in combating pulmonary infection in ICU

作　　者：朱会耕[1] 曹同瓦[1] 叶若兰[1] 刘华 

机构地区：[1]上海医科大学华山医院

出　　处：《中国抗生素杂志》1998年第4期298-299,305,共3页Chinese Journal of Antibiotics

摘　　要：将重症监护病房１１９例继发肺部感染病人随机分成两组，分别给予硫酸奈替米星３００ｍｇ／ｄ或阿米卡星６００ｍｇ／ｄ治疗，根据临床表现、白细胞计数、痰培养、胸片及肝肾功能等其它辅助检查，观察其疗效及不良反应。结果显示：硫酸奈替米星有效率（７９．７％）比阿米卡星（５７．８％）高；辅助检查中白细胞计数、胸片恢复正常率和痰培养转阴率前组均高于后组，而不良反应前组低于后组。本文认为：对重症监护病房肺部感染初期，痰培养及药敏尚未确定的病人，给予硫酸奈替米星３００ｍｇ／ｄ短程治疗是有效且安全的方案，尤其对老年人、小儿和有轻度肾功能损害者，在严密肾功能监护下，可有针对性使用。We divided the 119 ICU patients with lung infection into 2 random groups: A and B. We treated them with netilmicin and amikacin respectively. Before and after the treatment, the patients′ clinical signs, symptoms, WBC count, chest Xray and sputum bacteria examinations were observed. The clinical effective rate of the netilmicin group was 79.7% and that of amikacin group was 57.8%. The former had higher negative rate for sputum bacteria culture than the latter. So we come to a conclusion that before we find the pathogenic bacteria, it is safe and effective to choose netilmicin treating the ICU patients with lung infections, especialy for children and the elderly, including those with minor renal impairment under close monitoring. Therefore netilmicin has relatively higher antibiotic value in clinical application.

关 键 词：肺部感染 硫酸奈替米星 阿米卡星 ICU 

分 类 号：R563.05[医药卫生—呼吸系统] R969.4[医药卫生—内科学]